Humacyte, Inc. filings document a commercial-stage biotechnology issuer built around acellular tissue engineered vessels and related bioengineered human tissue programs. Its reports and 8-K filings cover operating results, product commercialization, clinical and regulatory disclosures, material agreements for Symvess distribution rights, and collaboration or licensing arrangements.
The company’s SEC record also includes capital-structure disclosures for common stock and redeemable warrants, equity offering arrangements, secured debt financing, and Nasdaq listing-rule notices. Proxy materials describe board matters, executive compensation, equity awards, shareholder voting items and other governance disclosures for HUMA.
Humacyte, Inc. director D. Scott Coward received an award of 125,000 stock options on October 6, 2026, with an exercise price of $0.478 per share and an expiration date of October 6, 2036. The first 25% becomes exercisable on October 6, 2027; thereafter, 1/48 becomes exercisable on the 6th of each month, with the options fully vested on October 6, 2030.
Humacyte, Inc. (HUMA) director Paul Brian Kuznik acquired an award of 125,000 stock options to buy common stock on October 6, 2026. The options have an exercise price of $0.478 per share and expire October 6, 2036. After the award, he directly held 125,000 options; the first 25% becomes exercisable on October 6, 2027.
Humacyte, Inc. director Paul Brian Kuznik reported 156,519 shares of common stock held directly and 65,719 shares held by his spouse, as of September 22, 2026.
On September 22, 2026, Humacyte, Inc. appointed Scott Coward as a Class I director, with a term expiring in 2028, and Paul Kuznik as a Class II director, with a term expiring in 2029. Coward, an attorney at K&L Gates since July 2026 and a former Exact Sciences executive, joins the Audit Committee. Kuznik, a medical technology executive with experience in vascular healthcare and cardiovascular devices, joins the Commercial Committee.
Each will participate in Humacyte’s previously disclosed non-employee director compensation program: a $50,000 annual cash retainer and $5,000 per annum for board committee service, both prorated in 2026 for partial-year service, plus an option to purchase 125,000 shares of common stock.
Humacyte, Inc. (HUMA) director Keith Anthony Jones purchased additional common shares. On September 14, 2026, he bought 10,000 shares of Humacyte common stock in an open-market or private transaction at $0.562 per share. After this purchase, he holds 50,000 shares directly. No Rule 10b5-1 trading plan is reported for this transaction.
Humacyte, Inc. (HUMA) has had its Redeemable Warrants removed from listing and/or registration on the Nasdaq Stock Market LLC under Section 12(b) of the Securities Exchange Act of 1934. These warrants were each exercisable for one share of common stock at an exercise price of $11.50. Nasdaq states that it has complied with its own rules and the requirements of 17 CFR 240.12d2-2(b) to strike this class of securities from listing, and that Humacyte has complied with the Exchange’s rules and 17 CFR 240.12d2-2(c) governing voluntary withdrawal. Nasdaq, through an authorized officer, certifies that it has reasonable grounds to believe it meets all requirements for filing Form 25.
Humacyte, Inc. (HUMA) director Keith Anthony Jones reported purchasing 10,000 shares of Humacyte common stock in an open market or private transaction on August 20, 2026 at a price of $0.693 per share. Following this transaction, he directly owns 40,000 shares of Humacyte common stock.
Humacyte, Inc. (HUMA) director Keith Anthony Jones purchased Humacyte common stock in the open market. On 2026-08-17, he bought 30,000 shares at a weighted average price of about $0.594 per share, resulting in direct holdings of 30,000 shares.
Fresenius Medical Care Holdings, Inc. and its parent Fresenius Medical Care AG filed Amendment No. 11 updating their ownership in Humacyte, Inc. common stock. They report beneficial ownership of 13,603,235 shares, representing 4.9% of Humacyte’s outstanding voting shares, based on 277,798,105 shares outstanding as of August 10, 2026.
The filing details a series of open-market sales between August 10 and August 17, 2026 under a Rule 10b5‑1 trading plan with Citigroup Global Markets Inc., after which the reporting persons ceased to beneficially own more than five percent of Humacyte’s common stock. It also notes that Cassie McLean became President and CEO of FMCH and a Management Board member and CEO of FME AG’s Care Delivery segment effective August 1, 2026, succeeding Craig Cordola following his retirement.